Through clinical programs advancing from discovery into Phase II across more than 900 study participants, we have built and validated a fully integrated mRNA platform spanning payload design, targeted LNP delivery, and scalable manufacturing. This foundation enables us to move beyond early proof-of-concept programs and pursue the true promise of mRNA therapeutics: programmable protein replacement for chronic metabolic disease and targeted in vivo immunotherapies for autoimmune conditions, delivered through technologies capable of directing mRNA payloads to specific cell types throughout the body.